BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Tel Aviv:TEVA), H. Lundbeck A/S (CSE:LUN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK); and Xadago safinamide...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

...inhibitor, into studies that could be pivotal for neuropathic pain. The company also has Xadago safinamide...
...partners in the U.S., Europe, Asia and Australia. Newron had €7 million in revenue from Xadago...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...drugs Myobloc rimabotulinumtoxinB for cervical dystonia and chronic sialorrhea and Apokyn apomorphine hydrochloride and Xadago safinamide...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Seika Pharma Co. Ltd. / Newron Pharmaceuticals S.p.A. (SIX:NWRN) / Eisai Co. Ltd. (Tokyo:4523) Xadago safinamide...
BioCentury | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

...410 Parkinson's disease patients with wearing-off phenomenon showing that once-daily 50 and 100 mg oral safinamide...
...Rating Scale (UPDRS), 39-item PD Questionnaire (PDQ-39), responder rate and safety. Safinamide is marketed as Xadago...
...Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Meiji Seika Pharma Co. Ltd., Tokyo, Japan Product: Xadago safinamide...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Apr 7, 2017
Finance

Fade to black

...Merkel cell carcinoma (MCC) Newron Pharmaceuticals S.p.A. (SIX:NWRN) / US WorldMeds LLC FDA approves Xadago safinamide...
BioCentury | Mar 23, 2017
Clinical News

Xadago regulatory update

...FDA approved an NDA for Xadago safinamide from Newron as an add-on treatment for patients with...
...responded to inquires regarding Xadago's launch date or price. Zambon, which has ex-Asian rights to Xadago...
...Bresso, Italy Meiji Seika Pharma Co. Ltd. , Tokyo, Japan Product: Xadago safinamide Business: Neurology Julian Zhu safinamide Xadago Meiji...
BioCentury | Mar 21, 2017
Company News

FDA approves Newron's Xadago

...FDA approved Xadago safinamide from Newron Pharmaceuticals S.p.A. (SIX:NWRN) as an add-on treatment for patients with...
...a complete response letter for the therapy. Newron said the agency requested clinical evaluation of Xadago's...
...Ky.) holds U.S. rights to Xadago. Neither Newron nor US WorldMeds responded to inquires regarding Xadago's...
BioCentury | Jan 20, 2017
Company News

Zambon, CSL deal

...Zambon granted CSL’s Seqirus unit exclusive rights to develop and commercialize Parkinson’s disease drug Xadago safinamide...
...to inquiries. Zambon Co. S.p.A. , Bresso, Italy CSL Ltd. (ASX:CSL), Melbourne, Australia Business: Neurology Alicia Parker safinamide Xadago CSL...
Items per page:
1 - 10 of 121